These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 1325106)

  • 21. Clarithromycin and azithromycin.
    Med Lett Drugs Ther; 1992 May; 34(870):45-7. PubMed ID: 1315414
    [No Abstract]   [Full Text] [Related]  

  • 22. Clarithromycin: review of a new macrolide antibiotic with improved microbiologic spectrum and favorable pharmacokinetic and adverse effect profiles.
    Sturgill MG; Rapp RP
    Ann Pharmacother; 1992 Sep; 26(9):1099-108. PubMed ID: 1421677
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of azithromycin and clarithromycin in clinical practice.
    Goldman MP; Longworth DL
    Cleve Clin J Med; 1993; 60(5):359-64. PubMed ID: 8403355
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Two new macrolide antibiotics: clarithromycin and azithromycin.
    Holdcroft C
    Nurse Pract; 1993 Jan; 18(1):50, 53. PubMed ID: 8380492
    [No Abstract]   [Full Text] [Related]  

  • 25. [Clarithromycin in the treatment of respiratory infections].
    Med Clin (Barc); 1991 Jun; 97(1):suppl 2 p.. PubMed ID: 1830354
    [No Abstract]   [Full Text] [Related]  

  • 26. Two macrolide antimicrobials approved for marketing.
    Clin Pharm; 1992 Feb; 11(2):98. PubMed ID: 1312922
    [No Abstract]   [Full Text] [Related]  

  • 27. Pharmacokinetic and pharmacodynamic interaction study between midazolam and the macrolide antibiotics, erythromycin, clarithromycin, and the azalide azithromycin.
    Yeates RA; Laufen H; Zimmermann T; Schumacher T
    Int J Clin Pharmacol Ther; 1997 Dec; 35(12):577-9. PubMed ID: 9455717
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetic and in vivo studies with azithromycin (CP-62,993), a new macrolide with an extended half-life and excellent tissue distribution.
    Girard AE; Girard D; English AR; Gootz TD; Cimochowski CR; Faiella JA; Haskell SL; Retsema JA
    Antimicrob Agents Chemother; 1987 Dec; 31(12):1948-54. PubMed ID: 2830841
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical implications of macrolide resistance in community-acquired respiratory tract infections.
    Hoban DJ; Zhanel GG
    Expert Rev Anti Infect Ther; 2006 Dec; 4(6):973-80. PubMed ID: 17181414
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New antibiotics look good against M. avium.
    Am J Nurs; 1992 Jan; 92(1):12. PubMed ID: 1309625
    [No Abstract]   [Full Text] [Related]  

  • 31. [Tissue penetration properties of macrolide antibiotics--comparative tissue distribution of erythromycin-stearate, clarithromycin, roxithromycin and azithromycin in rats].
    Yoshida H; Furuta T
    Jpn J Antibiot; 1999 Jul; 52(7):497-503. PubMed ID: 10516929
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and efficacy of Clarithromycin in the treatment of acute mild to moderate respiratory tract infections.
    O'Neill SJ; Millar ED; Coles SJ; Bachand RT
    Ir Med J; 1991 Mar; 84(1):33-5. PubMed ID: 1828461
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Azithromycin: an interim analysis.
    Ball AP
    J Int Med Res; 1991; 19(6):446-50. PubMed ID: 1663467
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Meta-analysis of bacterial resistance to macrolides.
    Halpern MT; Schmier JK; Snyder LM; Asche C; Sarocco PW; Lavin B; Nieman R; Mandell LA
    J Antimicrob Chemother; 2005 May; 55(5):748-57. PubMed ID: 15772147
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clarithromycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential.
    Peters DH; Clissold SP
    Drugs; 1992 Jul; 44(1):117-64. PubMed ID: 1379907
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative tolerability of erythromycin and newer macrolide antibacterials in paediatric patients.
    Principi N; Esposito S
    Drug Saf; 1999 Jan; 20(1):25-41. PubMed ID: 9935275
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The new macrolides. Azithromycin and clarithromycin.
    Kanatani MS; Guglielmo BJ
    West J Med; 1994 Jan; 160(1):31-7. PubMed ID: 8128699
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The in vitro activity of some 14-, 15- and 16- membered macrolides against Staphylococcus spp., Legionella spp., Mycoplasma spp. and Ureaplasma urealyticum.
    Felmingham D; Robbins MJ; Sanghrajka M; Leakey A; Ridgway GL
    Drugs Exp Clin Res; 1991; 17(2):91-9. PubMed ID: 1650694
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vivo evaluation of three acid-stable azalide compounds, L-701,677, L-708,299 and L-708,365 compared to erythromycin, azithromycin and clarithromycin.
    Gill CJ; Abruzzo GK; Flattery AM; Smith JG; Jackson J; Kong L; Wilkening R; Shankaran K; Kropp H; Bartizal K
    J Antibiot (Tokyo); 1995 Oct; 48(10):1141-7. PubMed ID: 7490222
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dental therapeutic indications for the newer long-acting macrolide antibiotics.
    Moore PA
    J Am Dent Assoc; 1999 Sep; 130(9):1341-3. PubMed ID: 10492541
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.